Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.72 |
| ▸ | MAOB | P27338 | 4/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | SDHA | P31040 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CALML3 | P27482 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950996 | 1.00 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6097822 | 1.00 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701350 | 0.92 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701349 | 0.92 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328441 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328443 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3753257 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL701373 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2088204 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3206976 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MAOA 3217/4885MAOB 2014/4885PTGS1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.